{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:32:50Z","timestamp":1773869570640,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.crad.2022.09.127","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T08:51:26Z","timestamp":1667551886000},"page":"e131-e136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy"],"prefix":"10.1016","volume":"78","author":[{"given":"Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.R.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Daud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.C.","family":"Behr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.crad.2022.09.127_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.crad.2022.09.127_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.crad.2022.09.127_bib3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.crad.2022.09.127_bib4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2022.09.127_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.crad.2022.09.127_bib6","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 anti- body therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.crad.2022.09.127_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.crad.2022.09.127_bib8","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","article-title":"Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma","volume":"149","author":"Danlos","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.crad.2022.09.127_bib9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crad.2022.09.127_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.crad.2022.09.127_bib11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","article-title":"Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab","volume":"27","author":"Cousin","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.crad.2022.09.127_bib12","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2022.09.127_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti- programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2022.09.127_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2214\/AJR.11.7483","article-title":"Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST","volume":"198","author":"Nishino","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.crad.2022.09.127_bib15","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.crad.2022.09.127_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2022.09.127_bib17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.crad.2022.09.127_bib18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.crad.2022.09.127_bib19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.crad.2022.09.127_bib20","first-page":"24","article-title":"Cells and cytokines involved in the pathogenesis of sarcoidosis","volume":"16","author":"Moller","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.crad.2022.09.127_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.crad.2022.09.127_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis","volume":"131","author":"Chorti","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2022.09.127_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.crad.2022.09.127_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.crad.2022.09.127_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2022.09.127_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2021.07.015","article-title":"Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study","volume":"156","author":"Cabanie","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926022006729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926022006729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:49:33Z","timestamp":1757868573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926022006729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0009926022006729"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2022.09.127","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2022.09.127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}